SANDOZ GROUP AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.06 CHF | +0.68% |
|
+1.90% | +18.70% |
| 07/06 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
| 22/05 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
Chart calendar Sandoz Group AG
d45c1580c7d0b8805ed9.U8SnprGT1fkoYJWGk4RiFcDZhWRUuGqmj0Q6BW5TNm8.EpORkdnl45RFU9rZp7BSerCT61Ya3xiT9xVVYBsQUgR-8uXnxOCgsX0q_g~097ef0ba5d41f8e551240476daf6d88a
Upcoming events on Sandoz Group AG
Past events on Sandoz Group AG
| 11/06/2024 | Stifel Swiss Equities Conference |
| 07/05/2024 12:30 pm | Q1 2024 Sales and Revenue Call |
| 07/05/2024 10:30 am | Q1 2024 Sales and Revenue Release |
| 30/04/2024 01:30 pm | Annual General Meeting |
| 13/03/2024 01:30 pm | Q4 2023 Earnings Call |
| 13/03/2024 11:30 am | Q4 2023 Earnings Release |
| 09/01/2024 10:30 am | JPMorgan Healthcare Conference |
| 28/11/2023 | The Redburn Atlantic CEO Conference |
| 14/11/2023 | Jefferies London Healthcare Conference |
| 02/11/2023 04:00 pm | ZKB Swiss Equity Conference |
| 30/10/2023 | JP Morgan EU Healthcare CEO Conference |
| 24/10/2023 07:30 pm | Q3 2023 Sales and Revenue Call |
| 24/10/2023 10:45 am | Q3 2023 Sales and Revenue Release |
Past dividends on Sandoz Group AG
| 03/05/2024 | Annual 0.45 CHF |
Annual results
| Fiscal Period | December | 2022 | 2023 | 2024 |
|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 9 647 9 612 0.36% | 10 292 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | 1 743 1 810 -3.72% | 2 025 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | 1 488 1 519 -2.07% | 1 761 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 1 102 | 130 791 -83.56% | 959 |
|
Net income Million USD | Released Forecast Spread | 848 | 77,0 545 -85.87% | 710 |
|
EPS USD | Released Forecast Spread | 0,00 | 0,18 1,29 -86.05% | 1,62 |
| Announcement Date | 18/08/23 | 13/03/24 | - |
Quarterly results
| Fiscal Period | December | 2023 S1 | 2023 Q3 | 2023 Q4 | 2023 S2 | 2024 Q1 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2 186 2 213 -1.22% | 2 543 2 486 2.29% | 4 880 4 856 0.49% | 2 492 2 607 -4.41% | |
|
EBITDA Million USD | Released Forecast Spread | 751 791 -5.06% | ||||
|
EBIT Million USD | Released Forecast Spread | 618 686 -9.91% | ||||
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 362 | ||||
|
Net income Million USD | Released Forecast Spread | 235 | ||||
| Announcement Date | 05/09/23 | 24/10/23 | 13/03/24 | 13/03/24 | 07/05/24 |
More events
Past sector events for Sandoz Group AG
| 28/05/2024 09:23 pm | WOCKHARDT LIMITED: Q4 2024 Earnings Release |
| 24/05/2024 08:24 pm | GLENMARK PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
| 22/05/2024 03:05 pm | SUN PHARMACEUTICAL INDUSTRIES LTD.: Q4 2024 Earnings Release |
| 22/05/2024 01:43 pm | STRIDES PHARMA SCIENCE LIMITED: Q4 2024 Earnings Release |
| 19/05/2024 12:16 pm | MIDDLE EAST PHARMACEUTICAL INDUSTRIES COMPANY: Q1 2024 Earnings Release |
| 17/05/2024 03:40 pm | ZYDUS LIFESCIENCES LIMITED: Q4 2024 Earnings Release |
| 16/05/2024 01:55 pm | CAPLIN POINT LABORATORIES LIMITED: Q4 2024 Earnings Release |
| 16/05/2024 11:45 am | KRKA, D. D.: Q1 2024 Earnings Release |
| 16/05/2024 | SAM CHUN DANG PHARM. CO., LTD: Q1 2024 Earnings Release |
| 16/05/2024 | CELLTRION PHARM, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- SDZ Stock
- Calendar Sandoz Group AG
